Navigation Links
Merck KGaA and Nano-Terra Announce Extension of Nanotechnology Solutions Alliance
Date:10/7/2008

Merck KGaA (EMD in North America) announced today the extension of its existing strategic alliance with Nano-Terra, Inc., a leading nanotechnology co-development company.

DARMSTADT, Germany (Business Wire EON) October 7, 2008 -- The original agreement between the companies, announced in February 2007, was to develop innovative, nanotechnology-based products and solutions based on Merck's materials.

After successfully meeting initial development milestones, this new agreement will focus on specific application development for Merck customers and moving the technical capabilities into the marketplace for commercialization.

Under the new agreement, which extends the partnership through 2011, Nano-Terra will develop novel application techniques for existing Merck materials which are designed to address market opportunities where smaller (micron and nanometer) feature sizes are required for certain printable electronics components. The Merck fabrication processes will be based on Nano-Terra's proprietary soft lithography technology, invented and pioneered by Professor George Whitesides of Harvard University, a co-founder of Nano-Terra, and the partners will share commercialization rights on a global basis. Terms of the agreement were not disclosed.

The new development work will be done at Nano-Terra's lab facilities in Cambridge, with close cooperation of a Merck scientific team and by EMD Chemicals, Merck's North American affiliate.

  • Thomas Geelhaar, Vice President Liquid Crystals R&D and Business Development Chemicals of Merck KGaA, said, "We were very pleased by the progress made in the initial stages of our relationship with Nano-Terra. We look forward to our continued collaboration with Professor Whitesides and his team, and to building on these developments to create specific products which we believe will provide significant benefits to our customers."

"Through its embrace of innovative technologies and applications, Merck continues to underscore its commitment as a pioneer in research and development," said Dr. Carmichael Roberts, Vice Chairman of Nano-Terra. "We are delighted to extend our working relationship with them and to enhance their exploration of how to best optimize materials to improve products and processes for its customers."

  • 2006, Merck bestowed on Professor Whitesides the prestigious Emanuel Merck Lectureship prize.

About Nano-Terra, Inc.

Nano-Terra is a privately-held research and development company which has field-exclusive licenses to more than 50 patents on work done by co-founder Dr. George Whitesides at the renowned Whitesides Lab at Harvard University, where he is the Woodford L. and Ann A. Flowers University Professor. He is the recipient of the 2007 Priestley Medal.

  • company leverages its intellectual property through co-development and other agreements with Fortune 500 industrial and manufacturing companies and the U.S. government. Nano-Terra's scientific methods can be used to fabricate advanced materials and devices that enhance existing products or create entirely new products in a broad range of areas. These include smart materials and surfaces; flexible electronics such as displays and electronic packaging; fuel cells, batteries and solar power devices; sensors; industrial products and processes; and a wide range of consumer goods. For more information, visit www.nanoterra.com.

About EMD Chemicals Inc.

  • Chemicals represents the North American chemical sector of Merck KGaA, Darmstadt, Germany. As an international organization with 1,100 employees and revenues of more than $US 350 million, EMD Chemicals focuses on specialty chemicals for pharmaceutical, biotech, cosmetic, agricultural, automotive, plastics, electronics and other industrial applications.

  • Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.subscribe.merck.de to register online, change your selection or discontinue this service.

Merck is a global pharmaceutical and chemical company with sales of EUR 6.3 billion in 2006, a history that began in 1668, and a future shaped about 35,000 employees (including Merck Serono) in 56 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

Read the full story at http://www.prweb.com/releases/merck_kgaa/emd_chemicals/prweb1443764.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. The African Medical and Research Foundation (AMREF) Honors Merck & Co., Inc. with Global Corporate Philanthropy Award
4. Merck & Co., Inc. Response to Todays New York Medicaid Suit
5. Mylan Vice Chairman and CEO Robert J. Coury to Ring NYSE Closing Bell(R) in Celebration of Merck Generics Acquisition
6. AHF Challenges Merck Over Steep Price of Its New AIDS Drug, Isentress
7. ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
8. Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
9. The Lanier Law Firm Announces $4.85 Billion National Vioxx Settlement With Merck & Co. Inc.
10. GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
11. ICx Technologies Works With Merck & Co., Inc. to Develop Cancer Diagnostic Technology
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Merck KGaA and Nano-Terra Announce Extension of Nanotechnology Solutions Alliance 
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... Milford, NJ (PRWEB) , ... October 13, 2017 , ... ... weekend at scenic Alexandria Park in Milford, NJ. This free event, sponsored by ... and physical activity. The fun run is geared towards children of all ages; ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/13/2017)... ... 13, 2017 , ... “The Journey: From the Mountains to the Mission Field”: ... souls in the Philippines. “The Journey: From the Mountains to the Mission Field” is ... Bible. She has taught all ages and currently teaches a class of ladies at ...
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/22/2017)... DIEGO , Sept. 22, 2017 AVACEN ... medical device is now successfully helping those with the ... Fibromyalgia diagnosed Amanda in Essex, ... dressed and washing my hair, experiencing no sleep at ... in painful spasm… I cannot recommend [the AVACEN 100] ...
(Date:9/19/2017)... ZirMed Inc ., a recognized leader in cloud-based revenue cycle ... ranked #1 by its users for the seventh consecutive year ... ZirMed was recognized as the top-ranked end-to-end revenue cycle management ... 200 beds and holds one of the longest #1 ranking ... ...
Breaking Medicine Technology: